𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lenalidomide therapy in systemic mastocytosis

✍ Scribed by Hanneke C. Kluin-Nelemans; Veronika Ferenc; Jaap J. van Doormaal; Charlotte van Iperen; Willem G. Peters; Cem Akin; Peter Valent

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
107 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Gastrointestinal involvement and manifes
Gastrointestinal involvement and manifestations in systemic mastocytosis
✍ Harry Sokol; Sophie Georgin-Lavialle; Catherine Grandpeix-Guyodo; Danielle Canio πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 97 KB

Mastocytosis is a rare and heterogeneous disease characterized by various biological and clinical features with different prognosis and treatments. The disease is usually divided into 2 categories: a pure cutaneous and a systemic disease. Clinical features can be related to mast cells' mediators rel

Phase II study of imatinib mesylate as t
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
✍ Arturo Vega-Ruiz; Jorge E. Cortes; Matjaz Sever; Taghi Manshouri; Alfonso QuintΓ‘ πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 375 KB

Gain-of-function D816V point mutation within the kinase domain of the transmembrane receptor KIT is found in the great majority of patients with systemic mastocytosis (SM) and is attractive therapeutic target. Twenty patients with SM were enrolled during 2003-2005 in phase II clinical trial with ima